Affimed to focus on innate immunity portfolio

23 May 2019

German clinical-stage biopharma company Affimed Therapeutics (Nasdaq: AFMD) has announced a plan to focus its research and development investments on advancing on-going and previously announced clinical trials for its innate cell engager candidates, AFM13 and AFM24.

As part of the strategic plan, Affimed will terminate the Phase I clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager. The company had put two clinical trials of the cancer treatment on hold back in October after one patient died and two others experienced life-threatening events in the high-dose group.

The company also provided an update on recent operational progress and reported financial results for the quarter ended March 31, 2019, but that was not enough to please investors, as Affimed’s shares dropped as much as 10% and closed down 6.9% at $3.09 in Nasdaq trading on Wednesday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK